down arrow

Cardiff Oncology, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US14147L1089
USD
2.16
0.12 (5.88%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.102.19

52 Week

1.905.64
Valuation
Technical
Day's Volume

CASH

422.49 k

Shareholding (Mar 2025)

FII

2.63%

Held by 31 FIIs

DII

78.41%

Held by 16 DIIs

Promoter

6.66%

How big is Cardiff Oncology, Inc.?

22-Jun-2025

As of Jun 18, Cardiff Oncology, Inc. has a market capitalization of 246.15 million, with net sales of 0.59 million and a net profit of -48.86 million over the latest four quarters. The company reported shareholder's funds of 82.95 million and total assets of 97.19 million as of Dec 24.

Market Cap: As of Jun 18, Cardiff Oncology, Inc. has a market capitalization of 246.15 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cardiff Oncology, Inc. reported net sales of 0.59 million and a net profit of -48.86 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 82.95 million and total assets of 97.19 million.

Read More

What does Cardiff Oncology, Inc. do?

22-Jun-2025

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments. As of March 2025, it has a market cap of $246.15 million, with net sales of $0 and a net loss of $13 million.

Overview: <BR>Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing treatment options for cancer patients within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 246.15 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.12 <BR>Return on Equity: -68.93% <BR>Price to Book: 3.47<BR><BR>Contact Details: <BR>Address: 11055 Flintkote Ave, SAN DIEGO CA: 92121-1220 <BR>Tel: ['1 858 9527570', '1 858 9527593'] <BR>Fax: 1 858 2174768 <BR>Website: https://cardiffoncology.com/

Read More

Who are in the management team of Cardiff Oncology, Inc.?

22-Jun-2025

As of March 2022, the management team of Cardiff Oncology, Inc. includes Dr. Rodney Markin (Chairman), Dr. Mark Erlander (CEO), and several independent directors: Dr. Thomas Adams, Dr. James Armitage, Dr. Paul Billings, Mr. John Brancaccio, and Dr. Gary Jacob. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Cardiff Oncology, Inc. includes the following individuals:<BR><BR>- Dr. Rodney Markin, Chairman of the Board<BR>- Dr. Mark Erlander, Chief Executive Officer and Director<BR>- Dr. Thomas Adams, Director<BR>- Dr. James Armitage, Independent Director<BR>- Dr. Paul Billings, Independent Director<BR>- Mr. John Brancaccio, Independent Director<BR>- Dr. Gary Jacob, Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Cardiff Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Cardiff Oncology, Inc. has shifted to a bearish trend, indicated by negative MACD signals and underperformance against the S&P 500, with a year-to-date return of -50.23%.

As of 15 August 2025, the technical trend for Cardiff Oncology, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the MACD, which is bearish on both weekly and monthly time frames. The daily moving averages also confirm a bearish outlook. Bollinger Bands and KST are mildly bearish on both weekly and monthly periods, while the Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly stance. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.23% compared to the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish sentiment with considerable weakness.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 148 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.20

stock-summary
Return on Equity

-87.05%

stock-summary
Price to Book

2.53

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-14 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.2%
0%
10.2%
6 Months
-38.46%
0%
-38.46%
1 Year
-16.6%
0%
-16.6%
2 Years
71.43%
0%
71.43%
3 Years
37.58%
0%
37.58%
4 Years
-58.78%
0%
-58.78%
5 Years
-89.47%
0%
-89.47%

Cardiff Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cardiff Oncology, Inc. technically bullish or bearish?

As of 15 August 2025, the technical trend for Cardiff Oncology, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the MACD, which is bearish on both weekly and monthly time frames. The daily moving averages also confirm a bearish outlook. Bollinger Bands and KST are mildly bearish on both weekly and monthly periods, while the Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly stance. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.23% compared to the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish sentiment with considerable weakness....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.39%
EBIT Growth (5y)
-204.55%
EBIT to Interest (avg)
-38.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.12
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
53.85%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.64
EV to EBIT
-3.43
EV to EBITDA
-3.47
EV to Capital Employed
-21.57
EV to Sales
178.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-68.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (12.3%)

Foreign Institutions

Held by 31 Foreign Institutions (2.63%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -17.80% vs -6.31% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.50",
          "val2": "-12.40",
          "chgp": "-16.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.90",
          "val2": "-11.80",
          "chgp": "-17.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-122,124.00%",
          "val2": "-76,963.20%",
          "chgp": "-4,516.08%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.00% vs 25.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -9.66% vs -6.98% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.20",
          "val2": "-45.00",
          "chgp": "-7.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.40",
          "val2": "-41.40",
          "chgp": "-9.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71,231.30%",
          "val2": "-93,057.40%",
          "chgp": "2,182.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.10
0.20
-50.00%
Operating Profit (PBDIT) excl Other Income
-14.50
-12.40
-16.94%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.90
-11.80
-17.80%
Operating Profit Margin (Excl OI)
-122,124.00%
-76,963.20%
-4,516.08%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -17.80% vs -6.31% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.70
0.50
40.00%
Operating Profit (PBDIT) excl Other Income
-48.20
-45.00
-7.11%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-45.40
-41.40
-9.66%
Operating Profit Margin (Excl OI)
-71,231.30%
-93,057.40%
2,182.61%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 40.00% vs 25.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -9.66% vs -6.98% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cardiff Oncology, Inc. stock-summary
stock-summary
Cardiff Oncology, Inc.
Pharmaceuticals & Biotechnology
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
Company Coordinates stock-summary
Company Details
11055 Flintkote Ave , SAN DIEGO CA : 92121-1220
stock-summary
Tel: 1 858 95275701 858 9527593
stock-summary
https://cardiffoncology.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."